Tumor-stroma ratio combined with PD-L1 identifies pancreatic ductal adenocarcinoma patients at risk for lymph node metastases
TSR served as a robust and reproducible biomarker that identifies patients at risk for LNM. TSR might be used to select treatment and management strategies for PDAC patients.
Authors
- Xianlong Chen (ORCID: https://orcid.org/0000-0002-3677-4281)
- Shuangni Yu (ORCID: https://orcid.org/0000-0002-3745-1097)
- Shanyue Sun (ORCID: https://orcid.org/0000-0002-3134-7299)
- Xinyuan Chen (ORCID: https://orcid.org/0009-0007-9191-2521)
- Jie Chen (ORCID: https://orcid.org/0000-0002-2658-9525)
- Jiapeng Zhao
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- Shandong Provincial Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- British Journal of Cancer
- Published
- 2025-04-17
- DOI
- https://doi.org/10.1038/s41416-025-03019-z
- Citations
- 4
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 4.18
Funders
- Peking Union Medical College Hospital
- Peking Union Medical College